{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:49Z","timestamp":1790115829130,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38565-w","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:24:47Z","timestamp":1774157087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Kinga","family":"Tyczy\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr K.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Z\u0142otowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"\u015awierkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"38565_CR1","doi-asserted-by":"crossref","unstructured":"Azuaga, A. B., Ramirez, J. & Canete, J. D. Psoriatic arthritis: pathogenesis and targeted therapies. Int. J. Mol. Sci.  24(5) (2023).","DOI":"10.3390\/ijms24054901"},{"issue":"1","key":"38565_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald, O. et al. Psoriatic arthritis. Nat. Rev. Dis. Primers. 7(1), 59 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"38565_CR3","unstructured":"Tiwari, V. & Brent, L. H. Psoriatic Arthritis. StatPearls. StatPearls Publishing Copyright \u00a9 2025 (StatPearls Publishing LLC., 2025)."},{"issue":"2","key":"38565_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3899\/jrheum.080691","volume":"36","author":"FC Wilson","year":"2009","unstructured":"Wilson, F. C. et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J. Rheumatol. 36(2), 361\u2013367 (2009).","journal-title":"J. Rheumatol."},{"issue":"5","key":"38565_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.semarthrit.2018.08.005","volume":"48","author":"A Polachek","year":"2019","unstructured":"Polachek, A. et al. Late onset psoriatic arthritis in a longitudinal cohort: disease presentation, activity over time and prognosis. Semin Arthritis Rheum. 48(5), 834\u2013839 (2019).","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"38565_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald, O., Haroon, M., Giles, J. T. & Winchester, R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res. Ther. 17(1), 115 (2015).","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl 1","key":"38565_CR7","doi-asserted-by":"publisher","first-page":"i44","DOI":"10.1136\/ard.2010.140574","volume":"70","author":"JD Reveille","year":"2011","unstructured":"Reveille, J. D. The genetic basis of spondyloarthritis. Ann. Rheum. Dis. 70(Suppl 1), i44\u201350 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"38565_CR8","first-page":"e27767","volume":"14","author":"A Gupta","year":"2022","unstructured":"Gupta, A. & Madke, B. Psoriasis a cause of cardiovascular diseases: A review Article. Cureus 14(8), e27767 (2022).","journal-title":"Cureus"},{"issue":"16","key":"38565_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl. J. Med. 352(16), 1685\u20131695 (2005).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"38565_CR10","first-page":"877","volume":"35","author":"L Eder","year":"2008","unstructured":"Eder, L. et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J. Rheumatol. 35(5), 877\u2013882 (2008).","journal-title":"J. Rheumatol."},{"key":"38565_CR11","doi-asserted-by":"publisher","first-page":"714321","DOI":"10.1155\/2012\/714321","volume":"2012","author":"TY Zhu","year":"2012","unstructured":"Zhu, T. Y., Li, E. K. & Tam, L. S. Cardiovascular risk in patients with psoriatic arthritis. Int. J. Rheumatol. 2012, 714321 (2012).","journal-title":"Int. J. Rheumatol."},{"issue":"6","key":"38565_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with Pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83(6), 706\u2013719 (2024).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"38565_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh, J. A. et al. Special article: 2018 American college of Rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 71(1), 5\u201332 (2019).","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"38565_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","volume":"22","author":"MM Asgari","year":"2013","unstructured":"Asgari, M. M. et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996\u20132009. Pharmacoepidemiol Drug Saf. 22(8), 842\u2013849 (2013).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"5","key":"38565_CR15","doi-asserted-by":"publisher","first-page":"e98024","DOI":"10.1371\/journal.pone.0098024","volume":"9","author":"S L\u00f6fvendahl","year":"2014","unstructured":"L\u00f6fvendahl, S. et al. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in Southern Sweden\u2013a population-based register study. PLoS One. 9(5), e98024 (2014).","journal-title":"PLoS One"},{"issue":"5","key":"38565_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.semarthrit.2010.05.002","volume":"40","author":"TJ Love","year":"2011","unstructured":"Love, T. J., Cai, T. & Karlson, E. W. Validation of psoriatic arthritis diagnoses in electronic medical records using natural Language processing. Semin Arthritis Rheum. 40(5), 413\u2013420 (2011).","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"38565_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco, E., Hsueh, L., McConeghy, K. W., Gravenstein, S. & Saade, E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med. Res. Methodol. 21(1), 241 (2021).","journal-title":"BMC Med. Res. Methodol."},{"issue":"11","key":"38565_CR18","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 33(11), 2167\u20132172 (2006).","journal-title":"J. Rheumatol."},{"issue":"7","key":"38565_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman, D. D. et al. Cardiovascular morbidity in psoriatic arthritis. Ann. Rheum. Dis. 68(7), 1131\u20131135 (2009).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl_1","key":"38565_CR20","first-page":"A11699","volume":"140","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Abstract 11699: psoriatic arthritis increases the risk of incident atrial Fibrillation - A Community-based study. Circulation 140(Suppl_1), A11699\u2013A (2019).","journal-title":"Circulation"},{"issue":"12","key":"38565_CR21","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3899\/jrheum.080314","volume":"35","author":"J Feld","year":"2008","unstructured":"Feld, J. et al. Electrocardiographic findings in psoriatic arthritis: a case-controlled study. J. Rheumatol. 35(12), 2379\u20132382 (2008).","journal-title":"J. Rheumatol."},{"issue":"1","key":"38565_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2025.03.055","volume":"93","author":"WJ Song","year":"2025","unstructured":"Song, W. J., Oh, S. & Yoon, H. S. Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study. J. Am. Acad. Dermatol. 93(1), 141\u2013149 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"38565_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","volume":"20","author":"JL Lee","year":"2018","unstructured":"Lee, J. L. et al. Biologics and cardiovascular events in inflammatory arthritis: a prospective National cohort study. Arthritis Res. Ther. 20(1), 171 (2018).","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"38565_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3899\/jrheum.2024-1032","volume":"52","author":"CT May Wang","year":"2025","unstructured":"May Wang, C. T., Huang, J. Y., Liao, P. L., Wei, J. C. & Leung, Y. Y. Risk of mortality of people with psoriasis and psoriatic arthritis in taiwan: A nationwide cohort study. J. Rheumatol. 52(6), 590\u2013597 (2025).","journal-title":"J. Rheumatol."},{"issue":"2","key":"38565_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3899\/jrheum.210159","volume":"49","author":"A Haddad","year":"2022","unstructured":"Haddad, A. et al. The association of psoriatic arthritis with All-cause mortality and leading causes of death in psoriatic arthritis. J. Rheumatol. 49(2), 165\u2013170 (2022).","journal-title":"J. Rheumatol."},{"issue":"5","key":"38565_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/jdv.13152","volume":"30","author":"O Ahlehoff","year":"2016","unstructured":"Ahlehoff, O. et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J. Eur. Acad. Dermatol. Venereol. 30(5), 819\u2013823 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"38565_CR27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/1346-8138.13398","volume":"43","author":"T Pina","year":"2016","unstructured":"Pina, T. et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J. Dermatol. 43(11), 1267\u20131272 (2016).","journal-title":"J. Dermatol."},{"issue":"6","key":"38565_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","volume":"155","author":"MP Lee","year":"2019","unstructured":"Lee, M. P. et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 155(6), 700\u2013707 (2019).","journal-title":"JAMA Dermatol."},{"issue":"5","key":"38565_CR29","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease, P. J. et al. Long-Term efficacy and safety of Risankizumab in patients with active psoriatic arthritis: results from a 76-Week phase 2 randomized trial. Rheumatol. Ther. 9(5), 1361\u20131375 (2022).","journal-title":"Rheumatol. Ther."},{"issue":"10230","key":"38565_CR30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease, P. J. et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230), 1126\u20131136 (2020).","journal-title":"Lancet"},{"issue":"12","key":"38565_CR31","first-page":"11","volume":"69","author":"S Duttagupta","year":"2022","unstructured":"Duttagupta, S. et al. Effectiveness of Framingham and ASCVD risk scores in predicting coronary artery Disease - A comparative study with syntax score. J. Assoc. Physicians India. 69(12), 11\u201312 (2022).","journal-title":"J. Assoc. Physicians India"},{"issue":"2","key":"38565_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/ehjcvp\/pvz033","volume":"6","author":"I Hollan","year":"2020","unstructured":"Hollan, I. et al. Lipid management in rheumatoid arthritis: a position paper of the working group on cardiovascular pharmacotherapy of the European society of cardiology. Eur. Heart J. Cardiovasc. Pharmacother. 6(2), 104\u2013114 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38565-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:15:29Z","timestamp":1774419329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38565-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38565"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38565-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study utilized de-identified data from the TriNetX Global Health Research Network. All patient data within the TriNetX network are de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule \u00a7\u00a0164.514(a), with certification of de-identification provided by a qualified expert as per \u00a7\u00a0164.514(b)(1). As the study involved the analysis of pre-existing, anonymized data without direct patient contact or intervention, Institutional Review Board (IRB) approval and individual patient consent were not required, in accordance with institutional policies and federal regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"9688"}}